Iovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤_老虎社区_美港股上老虎

Iovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤

美股速递06-04

Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准，用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步，为当地晚期黑色素瘤患者提供了一种新的治疗选择。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

远离中概股A股股权
·06-04
欧洲也开放，加上肺癌批准，估计这股能冲到100以上了
回复
1
举报
收起
- 远离中概股A股股权:
  一期都做完了，二期做完就批了
  06-05
  回复
  举报
- 好东西要一直拿着:
  肺癌中期数据还没出，早着呢
  06-05
  回复
  举报
- 好东西要一直拿着:
  肺癌早着呢，批准试验而已。
  06-05
  回复
  举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1126068070?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-04 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126068070","market":"us","top_or_hot":-1,"title":"Iovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤","media":"美股速递","content":"<p>Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准，用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步，为当地晚期黑色素瘤患者提供了一种新的治疗选择。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-04 04:05 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准，用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步，为当地晚期黑色素瘤患者提供了一种新的治疗选择。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"","article_id":"1126068070","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126068070","pubTimestamp":1780517115,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准，用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步，为当地晚期黑色素瘤患者提供了一种新的治疗选择。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Iovance Inc. Amtagvi ® (Lifileucel) gets Australian approval for the treatment of advanced melanoma","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准，用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步，为当地晚期黑色素瘤患者提供了一种新的治疗选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[{"id":571638367285488,"gmtCreate":1780584328648,"gmtModify":1780585431150,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":1,"wearingBadges":[],"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"htmlText":"欧洲也开放，加上肺癌批准，估计这股能冲到100以上了","listText":"欧洲也开放，加上肺癌批准，估计这股能冲到100以上了","text":"欧洲也开放，加上肺癌批准，估计这股能冲到100以上了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/571638367285488","repostId":1126068070,"repostType":2,"repost":{"id":"1126068070","kind":"news","weMediaInfo":{"introduction":"全球快讯第一时间播报","home_visible":1,"media_name":"美股速递","id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"pubTimestamp":1780517115,"share":"https://www.laohu8.com/m/news/1126068070?lang=zh_CN&edition=full","pubTime":"2026-06-04 04:05","market":"us","language":"zh","title":"Iovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1126068070","media":"美股速递","summary":"Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准，用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步，为当地晚期黑色素瘤患者提供了一种新的治疗选择。","content":"<p>Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准，用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步，为当地晚期黑色素瘤患者提供了一种新的治疗选择。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2026-06-04 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准，用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步，为当地晚期黑色素瘤患者提供了一种新的治疗选择。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc.","BK4139":"生物科技"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126068070","content_text":"Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准，用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步，为当地晚期黑色素瘤患者提供了一种新的治疗选择。","news_type":1,"symbols_score_info":{"IOVA":1}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":571767180657424,"gmtCreate":1780615780696,"gmtModify":1780623011270,"authorId":3452505216401608,"author":{"id":3452505216401608,"idStr":"3452505216401608","authorId":3452505216401608,"name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","vip":1,"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":571638367285488,"type":1,"supId":571681498047664,"prevId":0,"content":"一期都做完了，二期做完就批了","text":"一期都做完了，二期做完就批了","html":"一期都做完了，二期做完就批了"},{"id":571681598226944,"gmtCreate":1780594988733,"gmtModify":1780609017512,"authorId":3537417120281286,"author":{"id":3537417120281286,"idStr":"3537417120281286","authorId":3537417120281286,"name":"好东西要一直拿着","avatar":"https://static.tigerbbs.com/ed03e24159cdfb1a1cc9e0eb75d70106","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":571638367285488,"type":1,"supId":0,"prevId":0,"content":"肺癌中期数据还没出，早着呢","text":"肺癌中期数据还没出，早着呢","html":"肺癌中期数据还没出，早着呢"},{"id":571681498047664,"gmtCreate":1780594943467,"gmtModify":1780609017413,"authorId":3537417120281286,"author":{"id":3537417120281286,"idStr":"3537417120281286","authorId":3537417120281286,"name":"好东西要一直拿着","avatar":"https://static.tigerbbs.com/ed03e24159cdfb1a1cc9e0eb75d70106","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":571638367285488,"type":1,"supId":0,"prevId":0,"content":"肺癌早着呢，批准试验而已。","text":"肺癌早着呢，批准试验而已。","html":"肺癌早着呢，批准试验而已。"}],"langContent":"CN"}],"hasMoreComments":false,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}